 SOMERSET, N.J.--BUSINESS WIRE--Catalent, Inc. Catalent NYSE: CTLT, the leading global provider of development sciences and manufacturing platforms for medicines, including biotherapeutics; cell and gene therapies; and consumer health products, today announced that its wholly owned subsidiary, Catalent Pharma Solutions, Inc. the Operating Subsidiary, intends to offer, subject to market and other conditions, 450 million in aggregate principal amount of senior unsecured notes due 2030 